The function and meaning of receptor activator of NF-κB ligand in arterial calcification

Abstract

Osteoclast-like cells are known to inhibit arterial calcification. Receptor activator of NF-κB ligand (RANKL) is likely to act as an inducer of osteoclast-like cell differentiation. However, several studies have shown that RANKL promotes arterial calcification rather than inhibiting arterial calcification. The present study was conducted in order to investigate and elucidate this paradox. Firstly, RANKL was added into the media, and the monocyte precursor cells were cultured. Morphological observation and Tartrate resistant acid phosphatase (TRAP) staining were used to assess whether RANKL could induce the monocyte precursor cells to differentiate into osteoclast-like cells. During arterial calcification, in vivo and in vitro expression of RANKL and its inhibitor, osteoprotegerin (OPG), was detected by real-time PCR. The extent of osteoclast-like cell differentiation was also assessed. It was found RANKL could induce osteoclast-like cell differentiation. There was no in vivo or in vitro expression of osteoclast-like cells in the early stage of calcification. At that time, the ratio of RANKL to OPG was very low. In the late stage of calcification, a small amount of osteoclast-like cell expression coincided with a relatively high ratio of RANKL to OPG. According to the results, the ratio of RANKL to OPG was very low during most of the arterial calcification period. This made it possible for OPG to completely inhibit RANKL-induced osteoclast-like cell differentiation. This likely explains why RANKL had the ability to induce osteoclast-like cell differentiation but acted as a promoter of calcification instead.

Keywords

arterial calcification / receptor activator of NF-κB ligand / osteoprotegerin / osteoclast-like cells

References

[1] RennenbergRJ, SchurgersLJ, KroonAA, et al. . Arterial calcifications. J Cell Mol Med, 2010, 14(9): 2203-2210 PMCID: 3822559 PMID: 20716128

[2] NevenE, De SchutterTM, De BroeME, et al. . Cell biological and physicochemical aspects of arterial calcification. Kidney Int, 2011, 79(11): 1166-1177 PMID: 21412217

[3] DellegrottaglieS, SanzJ, RajagopalanS. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med, 2006, 6(5): 515-524 PMID: 16918372

[4] TysonKL, ReynoldsJL, McNairR, et al. . Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol, 2003, 23(3): 489-494 PMID: 12615658

[5] ShaoJS, CaiJ, TowlerDA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol, 2006, 26(7): 1423-1430 PMID: 16601233

[6] MassyZA, MentaverriR, MozarA, et al. . The pathophysiology of vascular calcification: are osteoclast-like cells the missing link. Diabetes Metab, 2008, 34(1): 16-20

[7] SimpsonCL, LindleyS, EisenbergC, et al. . Toward cell therapy for vascular calcification: osteoclast-mediated demineralization of calcified elastin. Cardiovasc Pathol, 2007, 16(1): 29-37 PMID: 17218212

[8] TrouvinAP, GoëbV. Receptor activator of nuclear factor- κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging, 2010, 19(5): 345-354

[9] XieH, XiePL, WuXP, et al. . Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. Cardiovasc Res, 2011, 92(2): 296-306 PMID: 21750093

[10] HelasS, GoettschC, SchoppetM, et al. . Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol, 2009, 175(2): 473-478 PMCID: 2716948 PMID: 19590040

[11] RoodmanGD, IbbotsonK M, DonaldBR, et al. . 1, 25-Dihydroxyvitamin D3 causes formation of multinucleated cells with several osteoclast characteristics in cultures of primate marrow. Proc Natl Acad Sci USA, 1985, 82(23): 8213-8217 PMCID: 391473 PMID: 3865222

[12] CastellotJJJ, FavreauLV, KarnovskyMJ, et al. . Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem, 1982, 257(19): 256-11

[13] GotoH, OsakiM, FukushimaT, et al. . Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression. Biomed Res, 2011, 32(1): 37-44 PMID: 21383509

[14] LiuC, WanJ, YangQ, et al. . Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats. J Huazhong Univ Sci Technolog Med Sci, 2008, 28(5): 535-538 PMID: 18846333

[15] ValdivielsoJM. Vascular calcification: types and mechanisms. Nefrologia, 2011, 31(2): 142-147 PMID: 21461006

[16] OlesenP, NguyenK, WogensenL, et al. . Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Circ Physiol, 2007, 292(2): H1058-H1064 PMID: 17056676

[17] MinH, MoronyS, SarosiI, et al. . Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med, 2000, 192(4): 463-474 PMCID: 2193236 PMID: 10952716

[18] OsakoMK, NakagamiH, KoibuchiN, et al. . Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res, 2010, 107(4): 466-475 PMID: 20595654

[19] PanizoS, CardusA, EncinasM, et al. . RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res, 2009, 104(9): 1041-1048 PMID: 19325147